MedTrace Logo

A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

NCT04161781 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-05-16

No results posted yet for this study

Summary

The purpose of the study is to test 18F-BMS-986229 positron emission tomography (PET) imaging a practical and safe way to check the status of esophageal, stomach, and gastroesophageal junction cancer.

Conditions

  • Esophagogastric Cancer
  • Esophagus Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Gastroesophageal Junction Squamous Cell Carcinoma

Interventions

DRUG

18F-BMS-986229 Injection

Single injection prior to scan

DRUG

IV 18F-BMS-986229

370 MBq administered intravenously prior to scan

DIAGNOSTIC_TEST

PET/CT Scan

Whole-body PET/CT (80 mA)

Sponsors & Collaborators

Principal Investigators

  • Yelena Janjigian, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-12
Primary Completion
2024-03-06
Completion
2024-03-06
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161781 on ClinicalTrials.gov